Navigation Links
Oncolytics Biotech Inc. announces approval for UK clinical trial
Date:10/24/2007

CALGARY, AB, --- October 24, 2007 - Oncolytics Biotech Inc. (Oncolytics) (TSX:ONC, NASDAQ:ONCY) announced that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for its Clinical Trial Application (CTA) to begin a clinical trial using intravenous administration of REOLYSIN® in combination with cyclophosphamide, a chemotherapeutic agent as well as immune modulator, in patients with advanced cancers. The Principal Investigators are Dr. James Spicer of Kings College in London, Dr. Johann de Bono and Dr. Kevin Harrington of The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, and Professor Hardev Pandha of the Royal Surrey County Hospital NHS Trust, Surrey and Mount Alvernia Hospitals.

The Company also intends to host a conference call Wednesday, October 24, 2007 to provide an update on its expanding clinical program. The dial-in details appear below.

We are really looking forward to treating patients in this trial, said Principal Investigator Dr. James Spicer. The hope is that it will provide valuable information about the relationship between oncolytic viral therapy and the immune response of the patient.

The trial (REO 012) is an open-label, dose-escalating, non-randomized trial of REOLYSIN® given intravenously with escalating doses of cyclophosphamide. A standard dose of REOLYSIN® is administered intravenously over five consecutive days, while an intravenous dose of cyclophosphamide is administered three days before REOLYSIN® treatment and continues through the course of the treatment cycle. The total number of patients studied will depend on the number of dose levels tested, but it is anticipated to be approximately 30 patients.


'/>"/>

Contact: Cathy Ward
cathy.ward@oncolytics.ca
403-670-7370
Oncolytics Biotech Inc.
Source:Eurekalert

Page: 1

Related medicine news :

1. Biotechnology industry expected to grow into a three billion dollar industry by 2002
2. Biotechnology on the lead
3. Panacea Biotech To Market Anthrax Vaccine
4. Commercialization of Biotech Discoveries, An Encouragement For Researchers
5. Biotech drug causing anemia-EPREX
6. Leading Biotech Companies Are Interested In Acquisition Of Smaller Companies
7. Biologicals Transfer Proposal between US and Indian Biotechnology
8. Finland and India to interact and cooperate in the filed of telemedicine and biotechnology
9. Vical Biotech and NIH jointly develops HIV vaccine
10. Biotechnology Initiatives Planned In Hyderabad
11. Biotech Osiris to go public
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Rochelle, NY, September 17, 2014Diffusion Tensor Imaging (DTI), ... detects microstructural changes in brain tissue, can help ... outcomes following mild traumatic brain injury compared to ... according to a new study published in ... Mary Ann Liebert, Inc., publishers . The ...
(Date:9/17/2014)... CORVALLIS, Ore. People with facial paralysis are perceived ... in the universal language of facial expression, a new ... , The findings highlight the important role the ... hold a prejudice against those with facial paralysis because ... of psychology in the College of Liberal Arts at ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Fasoo ... Security Testing (SAST) tool, at AppSec USA 2014 in ... 9 am to 6 pm at booth G4 inside ... of the leading software security conferences for developers, auditors, ... tool that provides developers and managers with the ability ...
(Date:9/17/2014)... Elsevier, a world-leading provider of scientific, technical and ... publication of a position statement by the European ... Maturitas on the topic of breast ... prevalent cancer in women, with slightly more than ... Mammography screening is a well-established method to detect ...
(Date:9/17/2014)... September 17, 2014 In ongoing ... Inc.’s Drug Benefit News (DBN) continues to find ... in its Aug. 8 issue , CVS Caremark ... lists for 2015 each cut more drugs than ... savings these exclusions are likely to achieve. Despite ...
Breaking Medicine News(10 mins):Health News:New MRI technique helps clinicians better predict outcomes following mild traumatic brain injury 2Health News:Lack of facial expression leads to perceptions of unhappiness, new OSU research shows 2Health News:Lack of facial expression leads to perceptions of unhappiness, new OSU research shows 3Health News:Fasoo to Introduce Their Testing Tool to Improve Software Security and Quality at AppSec USA 2014 2Health News:AIS Newsletter Continues to Find Industry Criticism of PBM Formulary Exclusion Lists 2Health News:AIS Newsletter Continues to Find Industry Criticism of PBM Formulary Exclusion Lists 3
... Netherlands / Rockville, MD, USA (September 22, 2010) ... Exchange: CRX) and the Aeras Global TB Vaccine Foundation ... trial in infants of the jointly developed tuberculosis (TB) ... of the trial is to test the safety and ...
... of Cincinnati (UC) researcher will receive $2.5 million over ... (NIDA) to support his work on a potential immunotherapy ... in the psychiatry and behavioral neuroscience department, is one ... Awards for Innovative Medication Development Research. Award winners receive ...
... HealthDay Reporter , TUESDAY, Sept. 21 (HealthDay ... suicide rates appear to be highest among residents of ... fresh research points to a possible explanation: high altitudes. ... and the high prevalence of gun ownership, may contribute ...
... therapies against cancer to be effective, scientists need to ... makes a cancer cell resistant to a drug and ... Lombardi Comprehensive Cancer Center and Fox Chase Cancer Center. ... , the investigators discuss how cancer cells activate a ...
... of Rhode Island Hospital, is the recipient of the ... Imaging Network (ACRIN). Dupuy received the award for leading ... (RFA) to reduce the pain of osseous metastases (cancer ... scientific paper published during the previous year that stands ...
... Physicians now have access to real time radiology ... Viewbox (patent pending) is a portable interface system ... specialist consultation to physicians using any internet-ready device. ... in transmitting patient information and offers a timely ...
Cached Medicine News:Health News:Aeras and Crucell announce Phase II clinical trial start in Kenya 2Health News:Aeras and Crucell announce Phase II clinical trial start in Kenya 3Health News:Aeras and Crucell announce Phase II clinical trial start in Kenya 4Health News:Researcher wins $2.5 million award from National Institute on Drug Abuse 2Health News:Is High Altitude Linked to Suicide Risk? 2Health News:Is High Altitude Linked to Suicide Risk? 3Health News:Targeted therapy triggers complex mechanism of resistance 2Health News:Targeted therapy triggers complex mechanism of resistance 3Health News:Targeted therapy triggers complex mechanism of resistance 4Health News:Rhode Island Hospital physician receives national award for research 2Health News:Virtual Viewbox offers portable radiology access for physicians 2
(Date:9/17/2014)... Sept. 17, 2014  The law firm McElroy, ... that it will serve as host for "Show ... the Risks of Healthcare Reform," a one-day conference ... delivery systems, reimbursement, compliance and enforcement in a ... Logo -  http://photos.prnewswire.com/prnh/20140916/146606 Logo -  ...
(Date:9/17/2014)... and LEIPZIG, Germany ... announced that it has entered into an exclusive ... development of antibody-based imaging agents to image CD4+ ... collaboration with Novotectid expands ImaginAb,s capability to precisely diagnose ... and autoimmune disease areas. The ability to image ...
(Date:9/17/2014)... LAWRENCEVILLE, N.J. , Sept. 17, 2014 /PRNewswire-USNewswire/ ... that details how to implement GS1 Standards to ... (DSCSA), and enhance patient safety and security in ... Applying GS1 Standards to U.S. Pharmaceutical Supply ... Chain Security Act , was developed in ...
Breaking Medicine Technology:Three Leading Healthcare Organizations Sponsor Conference to Examine Opportunities and Risks of Healthcare Reform for Providers 2ImaginAb Expands ImmunoPET Pipeline to Include CD4+ T-Cell Imaging 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 3New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: